Valbiotis SA
ALVAL
Company Profile
Business description
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
Contact
12F rue Paul VATINE
Perigny
La Rochelle17180
FRAT: +33 546286258
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
50
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,896.44 | 84.83 | -1.06% |
| DAX 40 | 22,889.17 | 409.72 | -1.76% |
| Dow JONES (US) | 46,100.96 | 464.78 | -1.00% |
| FTSE 100 | 10,378.50 | 13.71 | 0.13% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,613.79 | 227.15 | -1.04% |
| Nikkei 225 | 52,463.27 | 1,276.41 | -2.38% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,522.75 | 52.57 | -0.80% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |